DOP 402

DOP 402 is a novel small-molecule delta opioid receptor (DOR) ligand that was rationally designed based on the structure of naltrindole, a selective DOR antagonist. Developed by researchers at the University of Medicine and Dentistry of New Jersey (UMDNJ), DOP 402 has demonstrated potent anti-proliferative activity against human U266 multiple myeloma cells in vitro. Interestingly, while it maintains high affinity for the naltrindole binding site on these cells, its growth-inhibitory effects are believed to be mediated through a non-opioid receptor target. Preclinical studies suggest that DOP 402 and related compounds (such as DOP 108, 121, and 126) may serve as potential therapeutic agents for hematological malignancies like multiple myeloma.